Fresenius Medical Care AG & Co. KGaA Investor News Investor Relations Else-Kr ner-Str. 1 61352 Bad Homburg Germany Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North Ameri

Medical Care successfully places US$650 million and 300 million 10-year senior notes

Homburg, Germany - Fresenius Medical Care AG & Co. KGaA ("the company" or

"Fresenius Medical Care"), the world's largest provider of dialysis products and services, today announced

the pricing of US$-denominated and -denominated senior unsecured notes (together "the senior notes") in the

principal amounts of US$650 million and 300 million, respectively, both due 2021. The principal amount of the US$ senior

notes was increased from the amount initially offered of US$500 million.

coupon for the US$ senior notes will be 5.75 %. With a price of 99.060% at issuance, the yield to maturity will be 5.875 %. The

coupon for the senior notes will be 5.25 %. The senior notes were issued at par. Net proceeds amounting to approximately

US$1,033 million from the offering will be used to repay indebtedness, for acquisitions including the company's recently

announced acquisition of Euromedic's dialysis service business and for general corporate purposes to support the renal products

and services business.

Brosnan, chief financial officer of the company, commented: "We are pleased to have successfully completed these offerings.

This means a further improvement of our solid funding structure. And it also enhances our flexibility for further pursuing our

strategy of sustainable growth."

senior notes were offered by FMC Finance VII S.A., and the US$ senior notes were offered by Fresenius Medical Care US Finance,

Inc., both wholly owned subsidiaries of the company. The senior notes will be guaranteed on a senior basis jointly and severally

by the company, Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care Deutschland GmbH. The senior notes were not registered

under the Securities Act of 1933 as amended, but were offered to "qualified institutional buyers" in the United States

pursuant to the exemption from registration provided by Rule 144A under the Securities Act and in an "offshore transaction"

pursuant to Regulation S under the Securities Act. The senior notes may not be offered or sold in the United States without registration

or an applicable exemption from the registration requirements.

Fresenius Medical Care

Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of

chronic kidney failure, a condition that affects more than 1.89 million individuals worldwide. Through its network of 2,716 dialysis

clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to

210,191 patients around the globe. Fresenius Medical Care also is the world's leading provider of dialysis products such as hemodialysis

machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3)

and the New York Stock Exchange (FMS, FMS/P).

release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially

from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive

conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings,

and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co.

KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake

any responsibility to update the forward-looking statements in this release.

release does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for, underwrite

or otherwise acquire, any securities of FMC Finance VII S.A., or Fresenius Medical Care US Finance, Inc. or Fresenius Medical

Care or any present or future member of its group nor should it or any part of it form the basis of, or be relied on in connection

with, any contract to purchase or subscribe for any securities of FMC Finance VII S.A. or Fresenius Medical Care US Finance, Inc.

or Fresenius Medical Care or any member of its group. In particular, this release is not an offer of securities in the United

States of America (including its territories and possessions), and securities of FMC Finance VII S.A. and Fresenius Medical Care

US Finance, Inc. and Fresenius Medical Care may not be offered or sold in the United States of America absent registration under

the Securities Act of 1933, as amended, (which FMC Finance VII S.A. and Fresenius Medical Care US Finance, Inc. and Fresenius

Medical Care do not intend to effect) or pursuant to an applicable exemption from registration.